- Home
- SLN vs FAX Comparison
SLN vs FAX Comparison
Compare SLN & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLN | FAX |
|---|---|---|
| Founded | 1994 | 1986 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.5M | 594.5M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLN | FAX |
|---|---|---|
| Price | $19.58 | $12.88 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $33.00 | N/A |
| AVG Volume (30 Days) | ★ 912.4K | 238.2K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.09% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $559,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $130.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.19 | $12.57 |
| 52 Week High | $17.58 | $16.37 |
Technical Indicators
Market Signals| Indicator | SLN | FAX |
|---|---|---|
| Relative Strength Index (RSI) | 79.21 | 37.21 |
| Support Level | $4.97 | $12.60 |
| Resistance Level | N/A | $14.69 |
| Average True Range (ATR) | 0.56 | 0.19 |
| MACD | 0.60 | 0.04 |
| Stochastic Oscillator | 99.86 | 44.97 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.